Paul Badawi Sells 22,362 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 22,362 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $6.62, for a total value of $148,036.44. Following the sale, the chief executive officer owned 6,025,840 shares of the company’s stock, valued at $39,891,060.80. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $88,787.60.
• On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total value of $188,395.08.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $6.42 on Friday. The stock’s 50-day simple moving average is $7.77 and its 200 day simple moving average is $5.34. The firm has a market capitalization of $339.43 million, a PE ratio of -7.13 and a beta of 2.42. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.10. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The firm had revenue of $19.91 million during the quarter, compared to the consensus estimate of $17.74 million. On average, analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on SGHT shares. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a report on Monday, January 5th. Citigroup boosted their price objective on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Lake Street Capital increased their target price on Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Morgan Stanley lifted their price target on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.30.

Institutional Investors Weigh In On Sight Sciences

Institutional investors have recently made changes to their positions in the stock. Alliancebernstein L.P. raised its position in shares of Sight Sciences by 5.5% during the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock worth $118,000 after acquiring an additional 1,800 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after acquiring an additional 2,875 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Sight Sciences by 1.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock valued at $1,045,000 after purchasing an additional 3,051 shares during the period. CWM LLC increased its position in Sight Sciences by 70.2% during the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after purchasing an additional 3,137 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.